Inhibition of transferrin iron release increases in vitro drug carrier efficacy

Journal of Controlled Release

Volumn 117, Issue 3, 2007, Pages 403-412

  Lao, Bert J ^a   Tsai, Wen Lin P ^a   Mashayekhi, Foad ^a   Pham, Edward A ^a   Mason, Anne B ^b   Kamei, Daniel T ^a  

^a University of California   (United States)

^b UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

Diphtheria toxin; Drug carrier; Targeted cancer therapy; Trafficking; Transferrin

Indexed keywords

CELLS; DRUG PRODUCTS; IRON; MATHEMATICAL MODELS; PROTEINS;

DIPHTHERIA TOXIN; DRUG CARRIERS; TARGETED CANCER THERAPY; TRAFFICKING; TRANSFERRIN;

ENZYME INHIBITION;

CARBONIC ACID; DIPHTHERIA TOXIN; DRUG CARRIER; IRON; OXALIC ACID; TRANSFERRIN; TRANSFERRIN RECEPTOR;

ARTICLE; CANCER CELL; CONTROLLED STUDY; CYTOTOXICITY; DRUG CONJUGATION; DRUG EFFICACY; DRUG RELEASE; HELA CELL; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; MATHEMATICAL MODEL; PRIORITY JOURNAL;

ALGORITHMS; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; CARBONATES; DIPHTHERIA TOXIN; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HELA CELLS; HUMANS; IRON; LIGANDS; MODELS, STATISTICAL; OXALATES; TETRAZOLIUM SALTS; THIAZOLES; TRANSFERRIN;

EID: 33846794839     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2006.12.001     Document Type: Article

References (34)

1. Cazzola M., Bergamaschi G., Dezza L., and Arosio P. Manipulations of cellular iron metabolism for modulating normal and malignant cell proliferation: achievements and prospects. Blood 75 10 (1990) 1903-1919
2. Reizenstein P. Iron, free radicals and cancer. Med. Oncol. Tumor Pharmacother. 8 4 (1991) 229-233
3. Saul J.M., Annapragada A.V., and Bellamkonda R.V. A dual-ligand approach for enhancing targeting selectivity of therapeutic nanocarriers. J. Control. Release 114 3 (2006) 277-287
4. Kreitman R.J. Immunotoxins for targeted cancer therapy. AAPS J. 8 3 (2006) E532-E551
5. Lim C.J., and Shen W.C. Transferrin-oligomers as potential carriers in anticancer drug delivery. Pharm. Res. 21 11 (2004) 1985-1992
6. Lai H., Sasaki T., Singh N.P., and Messay A. Effects of artemisinin-tagged holotransferrin on cancer cells. Life Sci. 76 11 (2005) 1267-1279
7. Johnson V.G., Wilson D., Greenfield L., and Youle R.J. The role of the diphtheria toxin receptor in cytosol translocation. J. Biol. Chem. 263 3 (1988) 1295-1300
8. Beyer U., Rothern-Rutishauser B., Unger C., Wunderli-Allenspach H., and Kratz F. Differences in the intracellular distribution of acid-sensitive doxorubicin-protein conjugates in comparison to free and liposomal formulated doxorubicin as shown by confocal microscopy. Pharm. Res. 18 1 (2001) 29-38
9. Hu-Lieskovan S., Heidel J.D., Bartlett D.W., Davis M.E., and Triche T.J. Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma. Cancer Res. 65 19 (2005) 8984-8992
10. Tros De Ilarduya C., Bunuales M., Qian C., and Duzgunes N. Antitumoral activity of transferrin-lipoplexes carrying the IL-12 gene in the treatment of colon cancer. J. Drug Target. 14 8 (2006) 527-535
11. Maruyama K., Ishida O., Kasaoka S., Takizawa T., Utoguchi N., Shinohara A., Chiba M., Kobayashi H., Eriguchi M., and Yanagie H. Intracellular targeting of sodium mercaptoundecahydrododecaborate (BSH) to solid tumors by transferrin-PEG liposomes, for boron neutron-capture therapy (BNCT). J. Control. Release 98 2 (2004) 195-207
12. Chiu S.J., Liu S., Perrotti D., Marcucci G., and Lee R.J. Efficient delivery of a Bcl-2-specific antisense oligodeoxyribonucleotide (G3139) via transferrin receptor-targeted liposomes. J. Control. Release 112 2 (2006) 199-207
13. Weaver M., and Laske D.W. Transferrin receptor ligand-targeted toxin conjugate (Tf-CRM107) for therapy of malignant gliomas. J. Neuro-Oncol. 65 1 (2003) 3-13
14. Yazdi P.T., Wenning L.A., and Murphy R.M. Influence of cellular trafficking on protein synthesis inhibition of immunotoxins directed against the transferrin receptor. Cancer Res. 55 17 (1995) 3763-3771
15. Yazdi P.T., and Murphy R.M. Quantitative analysis of protein synthesis inhibition by transferrin-toxin conjugates. Cancer Res. 54 24 (1994) 6387-6394
16. Wenning L.A., Yazdi P.T., and Murphy R.M. Quantitative analysis of protein synthesis inhibition and recovery in CRM107 immunotoxin-treated HeLa cells. Biotechnol. Bioeng. 57 4 (1998) 484-496
17. Sarkar C.A., Lowenhaupt K., Horan T., Boone T.C., Tidor B., and Lauffenburger D.A. Rational cytokine design for increased lifetime and enhanced potency using pH-activated "histidine switching". Nat. Biotechnol. 20 9 (2002) 908-913
18. Hinton P.R., Johlfs M.G., Xiong J.M., Hanestad K., Ong K.C., Bullock C., Keller S., Tang M.T., Tso J.Y., Vasquez M., and Tsurushita N. Engineered human IgG antibodies with longer serum half-lives in primates. J. Biol. Chem. 279 8 (2004) 6213-6216
19. Ciechanover A., Schwartz A.L., Dautry-Varsat A., and Lodish H.F. Kinetics of internalization and recycling of transferrin and the transferrin receptor in a human hepatoma cell line. Effect of lysosomotropic agents. J. Biol. Chem. 258 16 (1983) 9681-9689
20. French A.R., and Lauffenburger D.A. Controlling receptor/ligand trafficking: effects of cellular and molecular properties on endosomal sorting. Ann. Biomed. Eng. 25 4 (1997) 690-707
21. Hentze M.W., Muckenthaler M.U., and Andrews N.C. Balancing acts: molecular control of mammalian iron metabolism. Cell 117 3 (2004) 285-297
22. Bali P.K., Zak O., and Aisen P. A new role for the transferrin receptor in the release of iron from transferrin. Biochemistry 30 2 (1991) 324-328
23. Lebron J.A., Bennett M.J., Vaughn D.E., Chirino A.J., Snow P.M., Mintier G.A., Feder J.N., and Bjorkman P.J. Crystal structure of the hemochromatosis protein HFE and characterization of its interaction with transferrin receptor. Cell 93 1 (1998) 111-123
24. Rao B.M., Lauffenburger D.A., and Wittrup K.D. Integrating cell-level kinetic modeling into the design of engineered protein therapeutics. Nat. Biotechnol. 23 2 (2005) 191-194
25. Halbrooks P.J., Mason A.B., Adams T.E., Briggs S.K., and Everse S.J. The oxalate effect on release of iron from human serum transferrin explained. J. Mol. Biol. 339 1 (2004) 217-226
26. Costello J., and Landwehr D.M. Determination of oxalate concentration in blood. Clin. Chem. 34 8 (1988) 1540-1544
27. Berczi A., Barabas K., Sizensky J.A., and Faulk W.P. Adriamycin conjugates of human transferrin bind transferrin receptors and kill K562 and HL60 cells. Arch. Biochem. Biophys. 300 1 (1993) 356-363
28. Gerweck L.E., Vijayappa S., and Kozin S. Tumor pH controls the in vivo efficacy of weak acid and base chemotherapeutics. Mol. Cancer Ther. 5 5 (2006) 1275-1279
29. Giannetti A.M., Halbrooks P.J., Mason A.B., Vogt T.M., Enns C.A., and Bjorkman P.J. The molecular mechanism for receptor-stimulated iron release from the plasma iron transport protein transferrin. Structure (Camb) 13 11 (2005) 1613-1623
30. Johnson M.B., and Enns C.A. Diferric transferrin regulates transferrin receptor 2 protein stability. Blood 104 13 (2004) 4287-4293
31. Aloj L., Jogoda E., Lang L., Caraco C., Neumann R.D., Sung C., and Eckelman W.C. Targeting of transferrin receptors in nude mice bearing A431 and LS174T xenografts with [18F]holo-transferrin: permeability and receptor dependence. J. Nucl. Med. 40 9 (1999) 1547-1555
32. Anthony D.A.L., and French R. Intracellular receptor/ligand sorting based on endosomal retention components. Biotechnol. Bioeng. 51 3 (1996) 281-297
33. Cheng Y., Zak O., Aisen P., Harrison S.C., and Walz T. Structure of the human transferrin receptor-transferrin complex. Cell 116 4 (2004) 565-576
34. Marsh M., Griffiths G., Dean G.E., Mellman I., and Helenius A. Three-dimensional structure of endosomes in BHK-21 cells. Proc. Natl. Acad. Sci. U. S. A. 83 9 (1986) 2899-2903